Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $261,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $87.00, for a total transaction of $261,000.00. Following the transaction, the director directly owned 3,000 shares of the company’s stock, valued at approximately $261,000. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.37, for a total transaction of $631,738.00.
• On Wednesday, April 1st, Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.42, for a total transaction of $392,932.00.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $85.59 on Thursday. Kymera Therapeutics, Inc. has a 1 year low of $28.06 and a 1 year high of $103.00. The firm has a market cap of $7.04 billion, a PE ratio of -23.97 and a beta of 2.06. The company has a 50 day simple moving average of $83.69 and a two-hundred day simple moving average of $77.72.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.82) earnings per share. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Barclays boosted their price objective on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a report on Tuesday, January 27th. Piper Sandler boosted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. UBS Group boosted their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Finally, Canaccord Genuity Group initiated coverage on shares of Kymera Therapeutics in a report on Wednesday, May 6th. They set a “buy” rating and a $106.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $118.10.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers raised its holdings in Kymera Therapeutics by 7.5% during the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after buying an additional 252 shares during the last quarter. First Trust Advisors LP increased its position in Kymera Therapeutics by 59.0% during the 1st quarter. First Trust Advisors LP now owns 93,617 shares of the company’s stock valued at $7,797,000 after purchasing an additional 34,755 shares during the period. PNC Financial Services Group Inc. increased its position in Kymera Therapeutics by 56.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after purchasing an additional 463 shares during the period. WCM Investment Management LLC increased its position in Kymera Therapeutics by 44.9% during the 1st quarter. WCM Investment Management LLC now owns 152,381 shares of the company’s stock valued at $12,111,000 after purchasing an additional 47,187 shares during the period. Finally, AlphaCentric Advisors LLC increased its position in Kymera Therapeutics by 6.1% during the 1st quarter. AlphaCentric Advisors LLC now owns 5,342 shares of the company’s stock valued at $445,000 after purchasing an additional 307 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.